论文部分内容阅读
目的:探讨血小板生成素受体的两种新配体—血小板生成素Ⅱ(TPOⅡ)在体内的生物学活性。方法:以Babl/c纯系小鼠为实验对象,通过腹腔连续7d分组注射提纯的TPOⅡ配体Ⅰ、人工合成的TPOⅡ配体Ⅱ及重组的人血小板生成素,并于第7d末测定小鼠外周血小板数量,分析TPOⅡ体內的生物学活性。结果:在实验第7d,TPOⅡ配体Ⅰ实验组小鼠外周血小板数明显高于同期阴性对照组(P<0.05),与rhTPO阳性对照组相比则无明显差异(P>0.05);第14d,TPOⅡ的两个实验组的血小板数均较同期阴性对照组明显升高(P<0.01);与阳性对照组相比亦无明显差异(P>0.05)。而且随实验时间的延长,TPOⅡ实验组及阳性对照组血小板数均呈升高趋势。结论:提纯的TPOⅡ配体Ⅰ促进小鼠外周血小板的产生,其升高血小板的能力与rhTPO无明显差别。
Objective: To investigate the biological activity of two new ligands of thrombopoietin receptor, thrombopoietin Ⅱ (TPO Ⅱ) in vivo. Methods: Pure Babl / c mice were used as experimental subjects. The purified TPO Ⅱ ligand I, TPO Ⅱ ligand and recombinant human thrombopoietin were injected intraperitoneally for 7 consecutive days. Peripheral platelet number, analysis of biological activity of TPO Ⅱ in vivo. Results: On the 7th day of experiment, the number of peripheral platelets in TPOⅡ ligand Ⅰ experimental group was significantly higher than that in the negative control group (P <0.05), but no significant difference compared with rhTPO positive control group (P> 0.05) (P <0.01). Compared with the positive control group, there was no significant difference (P> 0.05) between the two experimental groups. And with the extension of experimental time, TPOⅡ experimental group and positive control group platelet number showed an upward trend. Conclusion: The purified TPO Ⅱ ligand Ⅰ promotes the production of peripheral platelets in mice and its ability to increase platelets has no significant difference with rhTPO.